Table 4.
The linear- regression between multiple variables and ARR improvements (in log)
| Variable | Standardized coefficients- Beta | T | P-value |
|---|---|---|---|
| Constant (SE) | 0.417 (0.116) | 3.580 | 0.002 |
| Normalized Concentration of 6-TGNs | −0.489 | −2.689 | 0.013* |
| Excluded variables | |||
| Age of onset, year | 0.156 | 0.853 | 0.403 |
| Disease duration, months | 0.094 | 0.509 | 0.616 |
| Treatment duration, months | −0.200 | −1.106 | 0.281 |
| Pre-therapy EDSS score | 0.034 | 0.176 | 0.862 |
| Post-therapy EDSS score | 0.050 | 0.266 | 0.793 |
| Mean CSF protein, mg/dl | −0.038 | −0.198 | 0.845 |
| Mean Concentration of CSF IgG, mg/ml | −0.158 | −0.855 | 0.402 |
| CSF IgG index (n%) | −0.287 | −1.636 | 0.116 |
| Normalized Concentration of MMPNs | −0.150 | −0.751 | 0.461 |
NMOSD, AZA Azathioprine, BMI Body mass index, ARR Annual relapse rate, EDSS Expanded disability status scale, 6-TGN 6-thioguanine nucleotides, 6-MMPN 6-methylmercaptopurine nucleotides. All P-value <0.05 was considered statistically significant